The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients

The DBCG89D trial randomized high-risk early breast cancer patients to adjuvant CMF (cyclophosphamide, methotrexate and fluorouracil) or CEF (cyclophosphamide, epirubicin and fluorouracil). Prosigna assays were performed by researchers with no access to clinical data. Time to distant recurrence (DR)...

Descripción completa

Detalles Bibliográficos
Autores principales: Jensen, Maj-Britt, Lænkholm, Anne-Vibeke, Balslev, Eva, Buckingham, Wesley, Ferree, Sean, Glavicic, Vesna, Dupont Jensen, Jeanette, Søegaard Knoop, Ann, Mouridsen, Henning T., Nielsen, Dorte, Nielsen, Torsten O., Ejlertsen, Bent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7044229/
https://www.ncbi.nlm.nih.gov/pubmed/32140564
http://dx.doi.org/10.1038/s41523-020-0148-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7044229/
https://www.ncbi.nlm.nih.gov/pubmed/32140564
http://dx.doi.org/10.1038/s41523-020-0148-0

Ejemplares similares